EA201990218A1 - Антитела с низкой иммуногенностью и их применения - Google Patents

Антитела с низкой иммуногенностью и их применения

Info

Publication number
EA201990218A1
EA201990218A1 EA201990218A EA201990218A EA201990218A1 EA 201990218 A1 EA201990218 A1 EA 201990218A1 EA 201990218 A EA201990218 A EA 201990218A EA 201990218 A EA201990218 A EA 201990218A EA 201990218 A1 EA201990218 A1 EA 201990218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
low
immunogenity
application
methods
Prior art date
Application number
EA201990218A
Other languages
English (en)
Inventor
Джеффри К. Джонсон
Лоуренс Дерт
Хараламбос Хаддживассилиоу
Дзеонгхоон Сунь
Кандасами Харихаран
Original Assignee
Селджин Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджин Корпорейшн filed Critical Селджин Корпорейшн
Publication of EA201990218A1 publication Critical patent/EA201990218A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем документе предложены антитела и их антигенсвязывающие фрагменты, имеющие низкую иммуногенность или неиммуногенные у людей, и необязательно обладающие желаемыми свойствами для производства. Также предложены композиции, содержащие такие антитела или антигенсвязывающие фрагменты, способы применения таких антител и способы получения таких антител.
EA201990218A 2016-07-06 2017-07-05 Антитела с низкой иммуногенностью и их применения EA201990218A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359150P 2016-07-06 2016-07-06
PCT/US2017/040653 WO2018009499A1 (en) 2016-07-06 2017-07-05 Antibodies with low immunogenicity and uses thereof

Publications (1)

Publication Number Publication Date
EA201990218A1 true EA201990218A1 (ru) 2019-07-31

Family

ID=60913146

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990218A EA201990218A1 (ru) 2016-07-06 2017-07-05 Антитела с низкой иммуногенностью и их применения

Country Status (19)

Country Link
US (1) US11427632B2 (ru)
EP (1) EP3481862A4 (ru)
JP (1) JP7120989B2 (ru)
KR (1) KR20190035737A (ru)
CN (1) CN109689684B (ru)
AR (1) AR108975A1 (ru)
AU (1) AU2017292752B2 (ru)
BR (1) BR112019000166A2 (ru)
CA (1) CA3029977A1 (ru)
CL (1) CL2019000019A1 (ru)
CO (1) CO2019001112A2 (ru)
EA (1) EA201990218A1 (ru)
EC (1) ECSP19008417A (ru)
IL (1) IL264009A (ru)
MX (1) MX2019000172A (ru)
SG (1) SG11201811788SA (ru)
TW (1) TW201811824A (ru)
WO (1) WO2018009499A1 (ru)
ZA (1) ZA201900070B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TW202104260A (zh) * 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
US20230365681A1 (en) 2020-10-07 2023-11-16 Celgene Corporation Bispecific antibody treatment of lymphoid malignant neoplasm conditions
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9026912D0 (en) 1990-12-11 1991-01-30 Wessex Instrumentation Limited Reaction detection equipment
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP2316487B1 (en) * 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
KR20120125634A (ko) 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
US7354854B2 (en) 2005-05-24 2008-04-08 Texas Instruments Incorporated Nickel silicide method and structure
RU2425054C2 (ru) * 2005-06-01 2011-07-27 Микромет Аг Антитела против il2
US8101727B2 (en) 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
CA2673725C (en) 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
WO2011101791A1 (en) 2010-02-18 2011-08-25 Tcl Pharma Anti-cd28 humanized antibodies
HUE13746964T2 (hu) * 2012-02-06 2020-01-28 Inhibrx Inc CD47 antitestek és alkalmazási eljárásaik
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP4137518A1 (en) 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
SG11201704058TA (en) 2014-11-18 2017-06-29 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
CN108290948B (zh) * 2015-09-21 2021-10-29 伊拉兹马斯大学医疗中心 抗-cd47抗体及使用方法

Also Published As

Publication number Publication date
KR20190035737A (ko) 2019-04-03
US20190241654A1 (en) 2019-08-08
ECSP19008417A (es) 2019-02-28
ZA201900070B (en) 2023-08-30
CL2019000019A1 (es) 2019-06-28
EP3481862A4 (en) 2020-08-12
SG11201811788SA (en) 2019-01-30
AU2017292752A1 (en) 2019-01-24
CN109689684B (zh) 2022-09-23
AR108975A1 (es) 2018-10-17
EP3481862A1 (en) 2019-05-15
CA3029977A1 (en) 2018-01-11
JP2019524087A (ja) 2019-09-05
IL264009A (en) 2019-01-31
TW201811824A (zh) 2018-04-01
CO2019001112A2 (es) 2019-02-19
CN109689684A (zh) 2019-04-26
MX2019000172A (es) 2019-09-26
AU2017292752B2 (en) 2023-07-27
JP7120989B2 (ja) 2022-08-17
WO2018009499A1 (en) 2018-01-11
US11427632B2 (en) 2022-08-30
BR112019000166A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
CY1124118T1 (el) Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων
EA201990218A1 (ru) Антитела с низкой иммуногенностью и их применения
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12018501554A1 (en) Ror1 antibody compositions and related methods
PH12017500890A1 (en) Antibody drug conjugates
TN2018000076A1 (en) Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
ZA201807467B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EA201791485A1 (ru) Анти-cd47-антитела и их применения
WO2016191643A3 (en) Tigit-binding agents and uses thereof
MX2019007021A (es) Anticuerpos il-11ra.
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
WO2018031490A3 (en) Anti-ox40 binding proteins
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2017136659A3 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
AR105267A1 (es) Anticuerpos de unión a tau
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
WO2018069871A3 (en) Anti-kras binding proteins
EP3455261A4 (en) ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение